EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The efficacy of continuous infusion of monoclonal factor viii products in patients with hemophilia



The efficacy of continuous infusion of monoclonal factor viii products in patients with hemophilia



Transfusion (Bethesda) 30(3): 278




(PDF emailed within 1 workday: $29.90)

Accession: 033800244

Download citation: RISBibTeXText



Related references

Half-life, recovery and efficacy of continuous infusion monoclonal antibody purified factor IX in hemophilia B surgical, trauma, or severe spontaneous hemorrhage patients. Blood 90(10 SUPPL 1 PART 1): 35A, Nov 15, 1997

Continuous infusion of monoclonal antibody-purified factor VIII: Rational approach to serious hemorrhage in patients with allo/autoantibodies to factor VIII. American Journal of Hematology 45(2): 142-145, 1994

Lingual hemorrhage in a patient with hemophilia A complicated by a high titer inhibitor. Management by continuous infusion of monoclonal antibody-purified factor VIII. American Journal of Pediatric Hematology/Oncology 15(1): 107-110, 1993

Patient-specific model of factor VIII, the basis for continuous computer controled infusion of Factor VIII in hemophilia A treatment. Naunyn-Schmiedeberg's Archives of Pharmacology 356(4 SUPPL 1): R37, 1997

Use of the factor viii half time for designing continuous factor viii infusion in classic hemophilia. Pediatric Researchpart 2: 582, 1981

Efficacy and safety of recombinant factor VIII products in patients with hemophilia A. Drugs of Today 44(10): 735-750, 2009

Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B. Acta Haematologica 94 Suppl 1: 35-42, 1995

Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thrombosis and Haemostasis 86(4): 954-958, 2001

Continuous infusion therapy of factor viii concentrate in hemophilia a. Transfusion (Bethesda) 21(5): 621-622, 1981

Lack of immune response to mouse IgG in previously untreated hemophilia A and hemophilia B patients treated with monoclonal antibody purified factor VIII and factor IX preparations. Blood 86(10 SUPPL 1): 868A, 1995

The use of recombinant factor VIII products in previously treated patients with hemophilia A: pharmacokinetics, efficacy, safety, and inhibitor development. Seminars in Thrombosis and Hemostasis 28(3): 241-246, 2002

Treatment by continuous infusion with Monoclonal Antibody Purified factor IX in hemophilia B patients in surgical, trauma, or severe spontaneous hemorrhage. Blood 98(11 Part 1): 532a, November 16, 2001

Efficacy and safety of continuous infusion of recombinant factor VIIa in pediatric hemophilia A patients with high titer inhibitors. Blood 94(10 SUPPL 1 PART 1): 238a, Nov 15, 1999